# BeatAML Multi-Omics Integration Project
## Comprehensive Project Summary for Continuation

**Date Completed:** 2025-10-02

**Status:** Phases 1-6 Complete (Data Inventory & Planning Phase)

**Next Session:** Begin Tier 1 Core Analyses (Batch Correction & Molecular Subtyping)

---

## 🎯 WHAT WAS ACCOMPLISHED

### **Phases 1-6: Complete Data Inventory, QC, Power Analysis, and Documentation**

We completed a comprehensive analysis pipeline covering:
1. **Data Acquisition & Verification** - Confirmed all 5 BeatAML files present
2. **Data Exploration** - Characterized all 4 data types (expression, mutations, drug, clinical)
3. **Sample Mapping** - Created unified sample ID system across all datasets
4. **Quality Control** - Comprehensive QC revealing batch effects and 7 outliers
5. **Statistical Power Analysis** - Confirmed all 6 major analyses are feasible
6. **Master Documentation** - Created complete documentation suite

**Total Work:** 17 Python scripts, 60+ output files, comprehensive documentation

---

## 📊 KEY FINDINGS & NUMBERS YOU NEED TO KNOW

### **Sample Sizes (CRITICAL)**
- **Total unique samples:** 970
- **Gold Standard Cohort (all 4 data types):** **n=478** ← USE THIS FOR INTEGRATED ANALYSES
- **Expression only:** n=707
- **Mutations only:** n=871
- **Drug Response only:** n=603
- **Clinical only:** n=934
- **Survival data:** n=942 (565 deaths = 60% event rate)

### **Data Dimensions**
- **Expression:** 707 samples × 22,843 genes (269 MB)
- **Mutations:** 11,721 somatic mutations in 871 samples (615 genes mutated)
- **Drug Response:** 63,395 measurements (166 drugs × 603 samples)
- **Clinical:** 942 samples × 95 variables

### **Top 10 Driver Mutations (MEMORIZE THESE)**
1. DNMT3A: 22.5% (196 samples)
2. NPM1: 22.4% (195 samples)
3. NRAS: 13.5% (118 samples)
4. TET2: 13.4% (117 samples)
5. IDH2: 12.5% (109 samples)
6. SRSF2: 12.3% (107 samples)
7. RUNX1: 12.2% (106 samples)
8. ASXL1: 10.6% (92 samples)
9. FLT3: 9.8% (85 samples)
10. TP53: 9.3% (81 samples)

### **Quality Metrics**
- **Expression quality:** Mean sample correlation = 0.856 (excellent)
- **Outliers identified:** 7 samples (~1% of total) - flagged for review
- **Clinical completeness:** 100% survival, 97.2% age, 99.9% sex
- **Mutation quality:** Mean VAF = 0.341 (appropriate for AML)
- **Drug response:** No extreme values, mean 101 drugs/sample

---

## 🚨 CRITICAL ISSUE DISCOVERED

### **BATCH EFFECTS IN EXPRESSION DATA - REQUIRES IMMEDIATE ACTION**

**Finding:**
- Significant batch effects detected via PCA
- Source: `centerID` variable (sequencing center)
- Statistical significance:
  - PC1: F=24.5, p=9.07×10⁻³⁰
  - PC2: F=79.2, p=2.80×10⁻⁸³

**REQUIRED ACTION BEFORE ANY EXPRESSION ANALYSIS:**
```r
# Apply ComBat batch correction
library(sva)
batch <- clinical$centerID
batch_corrected_expr <- ComBat(dat=expression_matrix, batch=batch)
# Save corrected matrix
write.table(batch_corrected_expr, "beataml_expression_batchcorrected.txt")
```

**Status:** NOT YET DONE - THIS IS YOUR FIRST TASK IN NEXT SESSION

**Location of batch effect analysis:**
- Script: `02_Scripts/02_Quality_Control/01_batch_effect_assessment.py`
- Report: `03_Results/02_QC_Reports/batch_effect_assessment.txt`
- Figures: `04_Figures/01_QC_Figures/pca_by_batch_variable.png`

---

## 📁 FILE LOCATIONS (WHERE EVERYTHING IS)

### **Critical Master Files You'll Need:**

**1. Master Sample Mapping (MOST IMPORTANT FILE)**
```
03_Results/01_Processed_Data/master_sample_id_mapping.csv
```
- 970 samples with unified IDs
- Columns: unified_sample_id, expression_id, drug_response_id, clinical_id, mutation_id
- Boolean flags: has_expression, has_drug_response, has_clinical, has_mutations
- Cohort category for each sample

**2. Driver Mutation Frequencies**
```
03_Results/01_Processed_Data/driver_mutation_frequencies.csv
```
- All driver mutations with frequencies
- Use this to select mutations for analysis

**3. Power Analysis Results**
```
03_Results/02_QC_Reports/statistical_power_analysis.csv
```
- Shows all 6 analyses are feasible

**4. Comprehensive Roadmap**
```
05_Reports/Analysis_Roadmap.md
03_Results/03_Power_Analysis/consolidated_analysis_roadmap.csv
```
- 16 analyses across 3 tiers
- Detailed specifications for each

**5. Expression Outliers**
```
03_Results/02_QC_Reports/expression_outliers.csv
```
- 7 outlier samples identified
- Need to review before finalizing sample set

### **Raw Data Files (DON'T MODIFY THESE)**
```
01_Data/BeatAML_Downloaded_Data/
├── beataml_expression.txt (269 MB)
├── beataml_drug_auc.txt (3.5 MB)
├── beataml_clinical.xlsx (1.2 MB)
├── beataml_mutations.txt (5.8 MB)
└── beataml_raw_inhibitor.txt (48 MB)
```

### **All Results Organized In:**
```
03_Results/
├── 01_Processed_Data/ (22 CSV files)
├── 02_QC_Reports/ (12 reports)
└── 03_Power_Analysis/ (4 roadmap files)

04_Figures/
└── 01_QC_Figures/ (14 publication-quality PNG files)

05_Reports/
├── BeatAML_Data_Inventory_Report.md (MAIN REPORT - READ THIS FIRST)
├── Analysis_Cohort_Definitions.md
└── Analysis_Roadmap.md (DETAILED PLAN FOR ALL ANALYSES)

06_Documentation/
├── Data_Analysis_Log.txt (chronological log of everything done)
├── Data_Dictionary.md (complete variable definitions)
├── Analysis_Decisions.md (all major decisions documented)
└── Scripts_Index.md (all 17 scripts documented)
```

---

## 🗺️ ANALYSIS ROADMAP (WHAT TO DO NEXT)

### **16 Analyses Organized in 3 Tiers**

#### **TIER 1: Core Multi-Omics Analyses (HIGHEST PRIORITY)**

**Analysis 1.1: Molecular Subtyping via Expression**
- Goal: Identify transcriptomic subtypes in AML
- Sample size: n=707 (expression data)
- Power: 0.90
- Timeline: 2-3 weeks
- Method: Consensus clustering (k=3-5)
- **MUST DO FIRST:** Batch correction before this analysis
- Scripts location: `02_Scripts/04_Molecular_Subtyping/`

**Analysis 1.2: Comprehensive Mutation Landscape**
- Goal: Characterize mutational profile
- Sample size: n=871 (mutations)
- Power: 0.90
- Timeline: 1-2 weeks
- Deliverables: OncoPrint, co-occurrence matrix, mutation frequencies
- Scripts location: `02_Scripts/04_Molecular_Subtyping/`

**Analysis 1.3: Mutation-Expression Integration**
- Goal: How mutations affect gene expression
- Sample size: n=615 (expression + mutations)
- Power: 0.90 (10/10 key mutations powered)
- Timeline: 2-3 weeks
- Key comparisons: DNMT3A, NPM1, NRAS, TET2, IDH2 (all feasible)
- Scripts location: `02_Scripts/06_Integration/`

**Analysis 1.4: Drug Response Prediction**
- Goal: Predict drug sensitivity from expression + mutations
- Sample size: n=478 (gold standard cohort)
- Power: 0.85
- Timeline: 3-4 weeks
- Methods: Random Forest, Elastic Net, XGBoost
- Train/Val/Test split: 286/95/97
- Scripts location: `02_Scripts/05_Drug_Response/`

#### **TIER 2: Clinical Integration Analyses (6 analyses)**

See `Analysis_Roadmap.md` for complete details on:
- 2.1: Survival Analysis (n=942, 565 events)
- 2.2: Mutation-Drug Associations (n=583)
- 2.3: Network Analysis (n=478)
- 2.4: Survival by Molecular Features (n=942)
- 2.5: Clinical-Molecular Correlation (n=615)
- 2.6: Integrated Prognostic Model (n=615, 368 events)

#### **TIER 3: Advanced Integrative Analyses (6 analyses)**

See `Analysis_Roadmap.md` for:
- 3.1-3.6: Exploratory analyses, personalized medicine framework

### **Estimated Timeline**
- **Tier 1:** 8-12 weeks
- **Tier 2:** 7-10 weeks
- **Tier 3:** 11-16 weeks
- **Total:** 19-25 weeks with parallelization (~5-6 months)

---

## ⚡ IMMEDIATE NEXT STEPS FOR NEW SESSION

### **Week 1 (CRITICAL FOUNDATION)**

**Task 1: Apply Batch Correction (Day 1)**
```r
# R script
library(sva)
library(limma)

# Load expression data
expr <- read.table("01_Data/BeatAML_Downloaded_Data/beataml_expression.txt",
                   header=TRUE, row.names=1, sep="\t")

# Load clinical data for batch variable
clinical <- readxl::read_excel("01_Data/BeatAML_Downloaded_Data/beataml_clinical.xlsx")

# Extract batch variable (centerID)
batch <- clinical$centerID

# Apply ComBat
batch_corrected <- ComBat(dat=as.matrix(expr), batch=batch)

# Save
write.table(batch_corrected,
            "03_Results/01_Processed_Data/beataml_expression_batchcorrected.txt",
            sep="\t", quote=FALSE)

# Validate: Re-run PCA and check batch effects are removed
```

**Task 2: Review Outlier Samples (Day 1-2)**
- Open: `03_Results/02_QC_Reports/expression_outliers.csv`
- Review 7 outlier samples
- Decision: Keep or exclude?
- Document in: `06_Documentation/Analysis_Decisions.md`

**Task 3: Prepare Analysis-Ready Datasets (Day 2-3)**
- Load batch-corrected expression
- Filter gold standard cohort (n=478) from master mapping
- Prepare data matrices for Tier 1 analyses
- Save in: `03_Results/01_Processed_Data/`

**Task 4: Begin Analysis 1.1 - Molecular Subtyping (Day 4-5)**
- Use batch-corrected expression
- Select top 5000 most variable genes
- Run consensus clustering
- Test k=3, 4, 5, 6, 7
- Evaluate optimal k using gap statistic, silhouette width

---

## 📋 KEY DECISIONS ALREADY MADE (DON'T RE-DECIDE)

### **Data Processing**
✓ **Batch Correction:** APPLY ComBat (centerID variable)
✓ **Outliers:** Flag but don't auto-exclude (review before analysis)
✓ **Missing Data:** Analysis-specific handling (no imputation)
✓ **Gene Filtering:** Retain all 22,843 genes, filter per analysis

### **Cohort Definitions**
✓ **Primary Cohort:** Gold standard n=478 (all 4 data types) for integrated analyses
✓ **Secondary Cohorts:** Use analysis-specific cohorts to maximize power
✓ **Outlier Handling:** 7 samples flagged, to be reviewed

### **Statistical Thresholds**
✓ **Differential Expression:** FDR < 0.05, |log2FC| > 1.0
✓ **Clinical Associations:** p < 0.05, FDR < 0.10 for multiple tests
✓ **Survival:** p < 0.05 (log-rank), Cox p < 0.05
✓ **Drug Prediction:** R² > 0.3 acceptable, R² > 0.5 good

### **Software Choices**
✓ **R:** Statistical analyses (DESeq2, limma, survival, WGCNA)
✓ **Python:** Machine learning (scikit-learn, pandas)

---

## 🔍 WHERE TO FIND SPECIFIC INFORMATION

**"What are the sample sizes for analysis X?"**
→ `05_Reports/Analysis_Roadmap.md` or `03_Results/03_Power_Analysis/consolidated_analysis_roadmap.csv`

**"What mutations should I focus on?"**
→ `03_Results/01_Processed_Data/driver_mutation_frequencies.csv` - Top 20 listed

**"How do I map sample IDs across datasets?"**
→ `03_Results/01_Processed_Data/master_sample_id_mapping.csv` - THE MASTER FILE

**"What variables are in the clinical data?"**
→ `06_Documentation/Data_Dictionary.md` - Complete definitions

**"What quality issues exist?"**
→ `03_Results/02_QC_Reports/` - All QC reports
→ **Main issue:** Batch effects (needs correction)
→ **Minor issue:** 7 outliers (review recommended)

**"What decisions were made and why?"**
→ `06_Documentation/Analysis_Decisions.md` - All documented

**"What scripts exist and what do they do?"**
→ `06_Documentation/Scripts_Index.md` - Complete index

**"What did we do chronologically?"**
→ `06_Documentation/Data_Analysis_Log.txt` - Timestamped log

---

## 📊 STATISTICAL POWER (ALL ANALYSES FEASIBLE)

| Analysis | Sample Size | Power | Status |
|----------|-------------|-------|--------|
| Multi-omics Integration | 478 | 1.00 | ✓ Excellent |
| Molecular Subtyping | 707 | 0.90 | ✓ Excellent |
| Mutation-Expression | 615 | 0.90 | ✓ Excellent (10/10 genes) |
| Mutation-Drug | 583 | 0.80 | ✓ Good (5/5 pairs) |
| Survival Analysis | 942 | 0.90 | ✓ Excellent (565 events) |
| Predictive Modeling | 494 | 0.85 | ✓ Very Good |

**Mean Power Across All Analyses:** 0.89

**Conclusion:** ALL PLANNED ANALYSES ARE WELL-POWERED

---

## 🎓 SCIENTIFIC CONTEXT

### **Beat AML Dataset Overview**
- **Source:** Oregon Health & Science University
- **Access:** dbGaP controlled access (phs001657)
- **Publications:**
  - Tyner et al., Nature 2018 (primary)
  - Bottomly et al., Cancer Cell 2022 (drug response)

### **Our Project Goals**
1. Comprehensive multi-omics characterization of AML
2. Identify molecular subtypes with clinical relevance
3. Understand mutation-expression regulatory networks
4. Predict drug response from molecular features
5. Develop personalized treatment recommendation framework

### **Publication Targets**
- **3-5 high-impact papers**
- Target journals: Nature Communications, Cell Reports, Blood
- Themes: Multi-omics integration, drug prediction, personalized medicine

---

## 🐛 KNOWN ISSUES & CAVEATS

### **Issues Requiring Attention**

1. **Batch Effects (CRITICAL)**
   - Status: Detected but not yet corrected
   - Impact: Will confound expression-based analyses
   - Solution: Apply ComBat (Week 1, Task 1)

2. **Outlier Samples**
   - Status: 7 samples flagged
   - Impact: Minimal (~1%)
   - Solution: Review before finalizing (Week 1, Task 2)

3. **Sample ID Formats**
   - Expression: BA####R (RNA)
   - Mutations: BA####D (DNA)
   - Drug/Clinical: Various formats
   - Solution: Use master_sample_id_mapping.csv for all linking

### **Limitations to Remember**

- **Bulk tissue** (no single-cell resolution)
- **Cross-sectional** (no longitudinal data)
- **Single-agent drug screening** (no combination data)
- **Some ELN risk data missing** (variable not found in clinical file)

---

## 💾 DATA PRESERVATION

### **What NOT to Modify**
- `01_Data/BeatAML_Downloaded_Data/` - Original raw data (READ ONLY)
- `Archive_Previous_Analysis_20251002/` - Old analysis (DO NOT TOUCH)

### **What You Can Modify/Add**
- `02_Scripts/` - Add new analysis scripts
- `03_Results/` - Add new results
- `04_Figures/` - Add new figures
- `06_Documentation/Data_Analysis_Log.txt` - Add new entries

### **Critical Files to Protect**
- `master_sample_id_mapping.csv` - Don't overwrite
- `driver_mutation_frequencies.csv` - Reference only
- All QC reports - Keep for documentation

---

## 🔄 HOW TO CONTINUE IN NEW CHAT

### **Opening Statement for New Chat:**

```
I'm continuing work on the BeatAML Multi-Omics Integration project.
We've completed Phases 1-6 (data inventory, QC, power analysis, documentation).

CRITICAL CONTEXT:
- Gold standard cohort: n=478 with all 4 data types
- Batch effects detected in expression data (REQUIRES ComBat correction)
- All 6 major analyses are feasible (mean power=0.89)
- 7 outlier samples identified for review

IMMEDIATE NEXT STEPS (Week 1):
1. Apply ComBat batch correction to expression data
2. Review 7 outlier samples
3. Prepare analysis-ready datasets
4. Begin Analysis 1.1: Molecular Subtyping

KEY FILES:
- Project summary: D:\Projects\Project_AML\PROJECT_SUMMARY_FOR_CONTINUATION.md
- Main report: 05_Reports\BeatAML_Data_Inventory_Report.md
- Analysis roadmap: 05_Reports\Analysis_Roadmap.md
- Master mapping: 03_Results\01_Processed_Data\master_sample_id_mapping.csv

Please help me apply batch correction to the expression data using ComBat.
```

### **Files to Reference**
1. **This summary:** `PROJECT_SUMMARY_FOR_CONTINUATION.md`
2. **Main report:** `05_Reports/BeatAML_Data_Inventory_Report.md`
3. **Analysis roadmap:** `05_Reports/Analysis_Roadmap.md`
4. **Deliverables checklist:** `DELIVERABLES_CHECKLIST.md`

---

## 📈 SUCCESS METRICS

### **Phases 1-6: COMPLETE ✓**
- ✓ 17 Python scripts created and tested
- ✓ 60+ output files generated
- ✓ Comprehensive documentation suite
- ✓ All QC performed
- ✓ Power analysis complete
- ✓ Roadmap finalized

### **Next Milestones**
- Week 1: Batch correction applied
- Week 4: Molecular subtypes identified
- Week 6: Mutation landscape characterized
- Week 10: Drug prediction models complete
- Month 6: Tier 1 & 2 analyses complete

---

## 📞 QUICK REFERENCE

**Project Directory:** `D:\Projects\Project_AML\`

**Most Important Files:**
1. `master_sample_id_mapping.csv` (sample linking)
2. `driver_mutation_frequencies.csv` (mutation priorities)
3. `Analysis_Roadmap.md` (what to do)
4. `BeatAML_Data_Inventory_Report.md` (comprehensive summary)

**Critical Numbers:**
- Gold standard: n=478
- Top mutations: DNMT3A (22.5%), NPM1 (22.4%)
- Outliers: 7 samples
- Power: 0.89 (mean across analyses)

**Next Task:** Batch correction using ComBat (centerID variable)

---

## ✅ FINAL STATUS

**PROJECT HEALTH:** ✓ EXCELLENT

**Phases 1-6:** 100% COMPLETE

**Ready for Tier 1 Analyses:** YES

**Critical Issue:** Batch effects (straightforward fix)

**Timeline to First Results:** 4 weeks (molecular subtypes)

**Publication Potential:** HIGH (3-5 papers)

---

**END OF SUMMARY**

You now have everything needed to continue seamlessly in a new chat session. All work is documented, organized, and ready for the next phase.

Good luck with Tier 1 analyses! 🚀
